We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Weight-Loss Drug Qnexa Review Delayed By Late-Arriving REMS
Weight-Loss Drug Qnexa Review Delayed By Late-Arriving REMS
April 13, 2012
The FDA is delaying its action goal date on Vivus’ obesity drug Qnexa to July 17 after the company’s late submission of a risk evaluation and mitigation strategy (REMS).